Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates
09:17am, Wednesday, 28'th Apr 2021
Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alkermes: Q1 Earnings Insights
07:41am, Wednesday, 28'th Apr 2021
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11, which beat the estimate of ($0.0
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
07:05am, Wednesday, 28'th Apr 2021
DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engi
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence
04:01pm, Tuesday, 27'th Apr 2021
DUBLIN, April 27, 2021 /PRNewswire/ -- Myrelationshipwithalcohol.com, a new website sponsored by Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), goes live today to offer education about
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
07:00am, Tuesday, 27'th Apr 2021
DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of
Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results
04:00pm, Wednesday, 21'st Apr 2021
DUBLIN, April 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
09:51am, Thursday, 08'th Apr 2021
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., I
Alkermes to Take Part in Stifel's 3rd Annual CNS Day
04:00pm, Thursday, 25'th Mar 2021
DUBLIN, March 25, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on Thursday, Apr. 1, 202
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
07:00am, Thursday, 11'th Mar 2021
DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
06:10pm, Friday, 12'th Feb 2021
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
Alkermes plc (ALKS) CEO Richard Pops on Q4 2020 Results - Earnings Call Transcript
12:53pm, Thursday, 11'th Feb 2021
Alkermes plc (ALKS) CEO Richard Pops on Q4 2020 Results - Earnings Call Transcript
Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates
09:50am, Thursday, 11'th Feb 2021
Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
04:00pm, Thursday, 04'th Feb 2021
DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company'
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
08:00am, Monday, 04'th Jan 2021
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, pa
